| The multiple potential biomarkers for predicting immunotherapy response—Finding the needle in the haystack T Adam, TM Becker, W Chua, V Bray, TL Roberts Cancers 13 (2), 277, 2021 | 17 | 2021 |
| Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation … U Nindra, A Shahnam, S Stevens, A Pal, A Nagrial, J Lee, PY Yip, T Adam, ... Asia‐Pacific Journal of Clinical Oncology 20 (1), 16-24, 2024 | 5 | 2024 |
| Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab U Nindra, A Shahnam, S Stevens, A Pal, A Nagrial, J Lee, PY Yip, T Adam, ... Thoracic Cancer 13 (21), 3058-3062, 2022 | 5 | 2022 |
| 965P Real-world toxicity of consolidation durvalumab following chemoradiotherapy (CRT) in elderly and comorbid patients (pts) with unresectable stage III NSCLC: A multi-centre … S Stevens, U Nindra, A Shahnam, V Bray, A Pal, PY Yip, T Adam, ... Annals of Oncology 33, S989, 2022 | 3 | 2022 |
| Effect of delayed consolidation durvalumab and timing of treatment on survival outcomes in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated … SX Stevens, U Nindra, A Shahnam, VJ Bray, PY Yip, T Adam, JHJ Lee, ... Journal of Clinical Oncology 40 (16_suppl), e18809-e18809, 2022 | 1 | 2022 |
| Prognostic Nutritional Index (PNI) predicts progression free survival in patients with unresectable stage III non-small cell lung cancer treated with consolidation durvalumab U Nindra, A Shahnam, SX Stevens, A Pal, PY Yip, T Adam, J Lee, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 18, 166-166, 2022 | | 2022 |
| Patterns of care post progression for NSCLC patients treated with definitive chemoradiation and durvalumab A Shahnam, U Nindra, SX Stevens, V Bray, PY Yip, T Adam, J Lee, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 18, 140-141, 2022 | | 2022 |
| The prognostic influence of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in stage III non-small cell lung cancer (NSCLC) treated with … U Nindra, A Shahnam, SX Stevens, A Pal, PY Yip, T Adam, JHJ Lee, ... Journal of Clinical Oncology 40 (16_suppl), e18773-e18773, 2022 | | 2022 |
| The Multiple Potential Biomarkers for Predicting Immunotherapy Response—Finding the Needle in the Haystack. Cancers 2021, 13, 277 T Adam, TM Becker, W Chua, V Bray, TL Roberts s Note: MDPI stays neu-tral with regard to jurisdictional clai-ms in …, 2021 | | 2021 |
| Definitive chemoradiotherapy for stage II-III non-small cell lung cancer: Patient outcomes in South Western Sydney Local Health District T Adam, J Descallar, PY Yip, A Tognela, M Boxer, ML Yap, C Lee, ES Koh, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 14, 153-154, 2018 | | 2018 |
Tara RobertsAssociate Professor Oncology, Western Sydney UniversityVerified email at westernsydney.edu.au
